Literature DB >> 16042991

Suppression of fat deposition for the life time with gene therapy.

Stéphane Boghossian1, Anne Lecklin, Rita Torto, Pushpa S Kalra, Satya P Kalra.   

Abstract

Unexpended energy is stored as fat in the body and increased rate of fat accretion culminates in obesity. Obesity increases the risks of many diseases several folds and shortens life span. A progressive deficit in the central feedback effects of leptin, a peptide produced by fat cells and hypothalamus, results in increased weight gain and obesity. This article summarizes our experimental findings to show that a stable increase in leptin availability in the hypothalamus alone with the aid of leptin gene therapy suppresses fat accretion and metabolic hormones for nearly the lifetime of laboratory rodents. Consequently, central leptin gene therapy is a novel modality that offers a viable therapeutic option to reduce fat depots and attendant metabolic sequelae implicated in obesity-related illnesses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042991     DOI: 10.1016/j.peptides.2005.03.039

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

Review 1.  To subjugate NPY is to improve the quality of life and live longer.

Authors:  Satya P Kalra; Pushpa S Kalra
Journal:  Peptides       Date:  2007-01-09       Impact factor: 3.750

Review 2.  Adipokines and insulin resistance.

Authors:  Katja Rabe; Michael Lehrke; Klaus G Parhofer; Uli C Broedl
Journal:  Mol Med       Date:  2008-09-17       Impact factor: 6.354

3.  The lipoprivic control of feeding is governed by fat metabolism, not by leptin or adipose depletion.

Authors:  Bryan D Hudson; Alan J Emanuel; Michael F Wiater; Sue Ritter
Journal:  Endocrinology       Date:  2010-03-04       Impact factor: 4.736

4.  Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss.

Authors:  Russell T Turner; Michael Dube; Adam J Branscum; Carmen P Wong; Dawn A Olson; Xiaoying Zhong; Mercedes F Kweh; Iske V Larkin; Thomas J Wronski; Clifford J Rosen; Satya P Kalra; Urszula T Iwaniec
Journal:  J Endocrinol       Date:  2015-10-20       Impact factor: 4.286

5.  Effects of increased hypothalamic leptin gene expression on ovariectomy-induced bone loss in rats.

Authors:  M A Jackson; U T Iwaniec; R T Turner; T J Wronski; S P Kalra
Journal:  Peptides       Date:  2011-05-27       Impact factor: 3.750

6.  Hypothalamic leptin gene therapy prevents weight gain without long-term detrimental effects on bone in growing and skeletally mature female rats.

Authors:  Urszula T Iwaniec; Stéphane Boghossian; Cynthia H Trevisiol; Thomas J Wronski; Russell T Turner; Satya P Kalra
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

7.  Body mass influences cortical bone mass independent of leptin signaling.

Authors:  U T Iwaniec; M G Dube; S Boghossian; H Song; W G Helferich; R T Turner; S P Kalra
Journal:  Bone       Date:  2008-11-27       Impact factor: 4.398

8.  Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay.

Authors:  Satya P Kalra; Michael G Dube; Urszula T Iwaniec
Journal:  Peptides       Date:  2009-02-07       Impact factor: 3.750

Review 9.  Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2009-08-06       Impact factor: 3.750

Review 10.  Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches.

Authors:  Satya P Kalra
Journal:  Nutrition       Date:  2008-09       Impact factor: 4.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.